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Abstract
Bypass surgery for cancer of the pancreatic head is usually done to palliate the obstructive symptoms in the biliary
and/or digestive system. However, it is uncommon for patients to require pancreatic duct drainage for recurrent
obstructive pancreatitis. In this article, we report a surgical technique of triple bypass consisting of Roux-en-Y
hepaticojejunostomy, gastrojejunostomy, and pancreaticojejunostomy for advanced pancreatic cancer. A 76-year-old
male patient with locally advanced and metastatic pancreatic head cancer was referred to our department for biliary
stricture, duodenal stenosis, and recurrent obstructive pancreatitis associated with persistent pancreatic pseudocyst. In
an attempt to resolve all these problems simultaneously, a triple bypass was performed. The patient survived and
continued to receive chemotherapy for almost 1 year after surgery without any serious complications. Thus, triple
bypass is a useful surgical technique that could relief symptoms and offer better quality of life to patients with
advanced pancreatic cancer presenting with biliary stricture, duodenal stenosis, and severe obstructive pancreatitis
difficult to treat by medication or endoscopic procedures.
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Background
Despite an increasing incidence of pancreatic cancer
worldwide, the vast majority of patients with pancreatic
cancer are diagnosed at an unresectable stage. With new
advances in multimodal therapy and resulting increment
in the life expectancy of pancreatic cancer, the number
of patients with obstructive symptoms of the biliary and
gastrointestinal tract could increase. In fact, a recent
study has shown that the rate of patients with pancreatic
cancer presenting with symptomatic duodenal obstruc-
tion has increased [1]. Biliary and/or gastrointestinal
bypass, either surgically or endoscopically, is considered
to be a choice of treatment for such patients with unre-
sectable pancreatic cancer.
Bypass surgery for pancreatic cancer is usually done to
palliate the obstructive symptoms in the biliary and/or
digestive system. According to a large-scale analysis of
palliative surgery for pancreatic cancer, the bypass surgery
performed in 1126 patients included gastrojejunostomy
alone (33 %), bile duct bypass alone (27 %), both (31 %), or
cholecystojejunostomy (9 %) [2]. In some institutions in-
cluding our department, a palliative or prophylactic
double bypass (Roux-en-Y hepaticocholecystojejunostomy
plus gastrojejunostomy with Braun’s anastomosis) was
commonly used for patients with unresectable pancreatic
cancer. Although obstructive pancreatitis is often seen in
patients with pancreatic cancer, it is uncommon for these
patients to require pancreatic duct decompression.
In this report, we describe a procedure of bypass surgery,
namely triple bypass, to simultaneously resolve the obstruc-
tion of the biliary, gastrointestinal, and pancreatic ductal
systems. This novel technique can be safely and effectively
done in patients with pancreatic head cancer presenting
with obstructive jaundice, duodenal stenosis, and severe
obstructive pancreatitis.
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Case presentation
A 76-year-old male patient complaining of appetite loss
and upper abdominal pain was referred to our hospital
for examination of a mass detected in the pancreas.
Laboratory tests showed elevated levels of total and direct
bilirubin, amylase and lipase, and CA19-9. Abdominal CT
showed a low-density mass, measuring 40 × 30 mm, in the
pancreatic head associated with a marked dilatation of the
bile duct and distal pancreatic duct (Fig. 1a). The tumor
was diagnosed as borderline resectable according to the
NCCN guideline based on the finding that it contacted
the superior mesenteric vein of >180. There was also an
irregular-shaped cystic lesion spreading from the pancre-
atic tail to the splenic hilum, suggestive of a pancreatic
pseudocyst associated with severe obstructive pancreatitis
(Fig. 1b). A plastic biliary stent was placed endoscopically,
leading to a temporary relief of obstructive jaundice.
During neoadjuvant chemotherapy with gemcitabine
and S-1, a follow-up CT at 3 months detected multiple
metastases in the liver as well as a metastatic bone tumor
in the lumbar vertebrae. The plastic stent was occluded,
resulting in a severe cholangitis. Upper gastrointestinal
endoscopy showed stenosis of the duodenal lumen due to
a projection of the pancreatic head tumor, making it un-
able to approach the duodenal papilla for stent exchange.
The size of pancreatic pseudocyst at the splenic hilum
remained unchanged, and endoscopic drainage through
EUS was difficult because of its location. The patient also
had severe epigastric pain especially after diet resulting
from persistent pancreatitis associated with elevated
serum levels of amylase (502 U/l) and lipase (1167 U/l).
The patient needed to postpone a scheduled chemotherapy
for a month because of these symptoms and unsuccessful
endoscopic approaches, requiring a bypass surgery. In an at-
tempt to resolve all these problems simultaneously, a triple
bypass consisting of Roux-en-Y hepaticojejunostomy, gastro-
jejunostomy, and pancreaticojejunostomy was performed.
Surgical procedure
Under general anesthesia, an upper midline incision was
made on the abdomen. A firm mass in the pancreatic head
was confirmed, but no peritoneal dissemination was identi-
fied. First of all, the proximal jejunum was divided at ap-
proximately 15 cm from the Treitz ligament. The divided
jejunum was lifted to the hepatic hilum via the antecolic
route to make an anastomosis with the dilated common
hepatic duct (choledocojejunostomy). We also made chole-
cystojejunostomy because the cystic duct was also
obstructed and the gallbladder remained fully dilated even
after biliary drainage. We then lifted the distal jejunum to
the posterior gastric wall via the antecolic route to make a
gastrojejunostomy. We then dissected the anterior surface
of the pancreas and identified the markedly dilated main
pancreatic duct using intraoperative ultrasound. After mak-
ing a 5-cm opening on the main pancreatic duct, we made
an anastomosis between the jejunum and pancreatic duct
(with interrupted sutures). Finally, a Braun anastomosis was
added to complete the triple bypass procedure (Fig. 2).
Postoperative course
Postoperatively, the patient developed pancreatic fistula,
which could be managed conservatively by fasting and
drain maintenance. The levels of amylase and lipase de-
creased to the normal ranges and postoperative CT
showed improvements in the pseudocyst in the splenic
hilum. The patient was able to restart diet without
triggering any abdominal symptoms and was discharged
on postoperative day 27. After discharge, the patient im-
mediately started to have chemotherapy with gemcita-
bine plus S-1 and was able to continue for 11 months,
without any signs of biliary obstruction or abdominal
fullness. However, at 12 months after bypass surgery, the
patient died of pancreatic cancer spreading to the
peritoneum, causing bowel obstruction and cachexia.
Fig. 1 Abdominal CT showing a low-density mass, measuring 40 × 30 mm, in the pancreatic head associated with a marked dilatation of the bile
duct and distal pancreatic duct (a). There was also an irregular-shaped cystic lesion spreading from the pancreatic tail to the splenic hilum, suggestive
of a pancreatic pseudocyst associated with severe obstructive pancreatitis (b)
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Discussion
Despite the recent introduction of endoscopic interven-
tions, bypass surgery remains a treatment of choice for
palliating symptoms in patients with advanced pancre-
atic cancer. Bypass surgery for cancer of the pancreatic
head is usually done to relieve the obstructive symptoms
in the biliary and/or digestive system. However, it is un-
common for such patients to require pancreatic duct
drainage for recurrent obstructive pancreatitis. In this
article, we report a surgical technique of triple bypass
consisting of Roux-en-Y hepaticojejunostomy, gastrojeju-
nostomy, and pancreaticojejunostomy. Although triple
bypass is a complex procedure, this technique can sim-
ultaneously resolve the three problems in patients with
advanced pancreatic cancer, including obstructive
jaundice, duodenal stenosis, and recurrent obstructive
pancreatitis. In more specific, we selected triple bypass
for this particular case because of the following reasons:
(i) Although biliary obstruction in the present case was
initially treated by endoscopic stent placement, repeated
endoscopic approach to the papilla for stent exchange
was subsequently impossible due to exacerbated duo-
denal stenosis; (ii) The patient complained of nausea and
appetite loss possibly due to duodenal stenosis; (iii) The
patient suffered from recurrent obstructive pancreatitis
associated with pancreatic pseudocyst untreatable by
medication or endoscopic procedures.
Recently, endoscopic stent placement for biliary
obstruction has been increasingly used as a less invasive
alternative to bypass surgery. Recent meta-analysis has
shown that endoscopic stenting with plastic stents is
associated with a lower risk of complications (RR 0.60,
95 % CI 0.45–0.81) but a higher risk of recurrent biliary
obstruction (RR 18.59, 95 % CI 5.33–64.86) than
traditional surgical bypass [3]. Distler et al. compared the
outcomes of treatment, complications, and survival times
between endoscopic stent placement and hepaticojeju-
nostomy for patients with pancreatic head cancer [4]. The
authors showed that the mean interval between stent
exchanges was 70.8 days because of stent occlusion in pa-
tients who were treated with biliary stenting alone. In
addition, median survival for patients treated with an endo-
scopic stenting was significantly shorter than that for pa-
tients who were first stented and subsequently treated with
hepaticojejunostomy [4]. With recent introduction of more
effective chemotherapeutic regimens, including FOLFIRI-
NOX [5] and gemcitabine plus nab-paclitaxel [6], the life-
time of patients with advanced pancreatic cancer could be
longer than before. In this regard, bypass surgery or endo-
scopic placement of stents with a longer patency may be re-
quired for patients to benefit these effective chemotherapy.
Obstructive pancreatitis is a common complication in
patients with pancreatic head tumor. Although it is slow
progressive in most cases, obstructive pancreatic is
sometimes associated with severe pain and symptoms as
seen in patients with chronic pancreatitis. Previous
studies reported treatment of “obstructive” pain by
endoscopic pancreatic duct drainage in patients with
pancreatic head cancer [7, 8]. However, this endoscopic
approach is impossible for patients with duodenal sten-
osis secondary to a pancreatic tumor. Our approach of
pancreaticojejunostomy in addition to the biliary and
gastrointestinal bypass could be a treatment of choice
for severe obstructive pancreatitis associated with pain.
Fig. 2 A surgical procedure of triple bypass, consisting choledochojejunostomy (cholecystojejunostomy), gastrojejunostomy, and pancreaticojejunostomy
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Conclusions
In summary, we describe a surgical technique of triple
bypass, consisting of Roux-en-Y hepaticojejunostomy,
gastrojejunostomy, and pancreaticojejunostomy. This
procedure is useful for patients with pancreatic cancer
suffering from biliary stricture, duodenal stenosis, and
severe obstructive pancreatitis, especially those with a
persistent pancreatic pseudocyst untreatable by medica-
tion or endoscopic procedures.
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